The	0	3	O
antiangiogenic	4	18	O
agent	19	24	O
linomide	25	33	B-Drug_or_compound
inhibits	34	42	O
the	43	46	O
growth	47	53	O
rate	54	58	O
of	59	61	O
von	62	65	B-Pathological_formation
Hippel	66	72	I-Pathological_formation
-	72	73	I-Pathological_formation
Lindau	73	79	I-Pathological_formation
paraganglioma	80	93	I-Pathological_formation
xenografts	94	104	I-Pathological_formation
to	105	107	O
mice	108	112	B-Organism
.	112	113	O

The	115	118	O
aim	119	122	O
of	123	125	O
this	126	130	O
study	131	136	O
was	137	140	O
to	141	143	O
ascertain	144	153	O
the	154	157	O
potential	158	167	O
usefulness	168	178	O
of	179	181	O
the	182	185	O
antiangiogenic	186	200	O
compound	201	209	O
linomide	210	218	B-Drug_or_compound
for	219	222	O
treatment	223	232	O
of	233	235	O
von	236	239	B-Pathological_formation
Hippel	240	246	I-Pathological_formation
-	246	247	I-Pathological_formation
Lindau	247	253	I-Pathological_formation
(	254	255	I-Pathological_formation
VHL	255	258	I-Pathological_formation
)	258	259	I-Pathological_formation
-	259	260	I-Pathological_formation
related	260	267	I-Pathological_formation
tumors	268	274	I-Pathological_formation
.	274	275	O

Paraganglioma	276	289	B-Tissue
tissue	290	296	I-Tissue
fragments	297	306	I-Tissue
obtained	307	315	O
at	316	318	O
surgery	319	326	O
from	327	331	O
a	332	333	O
VHL	334	337	O
type	338	342	O
2a	343	345	O
patient	346	353	B-Organism
were	354	358	O
transplanted	359	371	O
s	372	373	O
.	373	374	O
c	374	375	O
.	375	376	O
to	377	379	O
male	380	384	O
BALB	385	389	B-Organism
/	389	390	I-Organism
c	390	391	I-Organism
nu	392	394	I-Organism
/	394	395	I-Organism
nu	395	397	I-Organism
(	398	399	I-Organism
nude	399	403	I-Organism
)	403	404	I-Organism
mice	405	409	I-Organism
:	409	410	O
(	411	412	O
a	412	413	O
)	413	414	O
2	415	416	O
-	416	417	O
3	417	418	O
-	418	419	O
mm	419	421	O
fragments	422	431	O
for	432	435	O
"	436	437	O
prevention	437	447	O
"	447	448	O
experiments	449	460	O
;	460	461	O
and	462	465	O
(	466	467	O
b	467	468	O
)	468	469	O
2	470	471	O
-	471	472	O
3	472	473	O
-	473	474	O
mm	474	476	O
fragments	477	486	O
allowed	487	494	O
to	495	497	O
grow	498	502	O
to	503	505	O
1	506	507	O
cm	508	510	O
for	511	514	O
"	515	516	O
intervention	516	528	O
"	528	529	O
studies	530	537	O
.	537	538	O

Both	539	543	O
groups	544	550	O
received	551	559	O
either	560	566	O
0	567	568	O
.	568	569	O
5	569	570	O
mg	571	573	O
/	573	574	O
ml	574	576	O
linomide	577	585	B-Drug_or_compound
in	586	588	O
drinking	589	597	O
water	598	603	O
or	604	606	O
acidified	607	616	O
water	617	622	O
and	623	626	O
were	627	631	O
followed	632	640	O
until	641	646	O
tumor	647	652	B-Pathological_formation
diameter	653	661	O
reached	662	669	O
3	670	671	O
cm	672	674	O
or	675	677	O
for	678	681	O
4	682	683	O
weeks	684	689	O
.	689	690	O

In	691	693	O
both	694	698	O
the	699	702	O
prevention	703	713	O
and	714	717	O
intervention	718	730	O
experiments	731	742	O
,	742	743	O
a	744	745	O
significant	746	757	O
diminution	758	768	O
of	769	771	O
tumor	772	777	B-Pathological_formation
size	778	782	O
and	783	786	O
weight	787	793	O
was	794	797	O
observed	798	806	O
in	807	809	O
the	810	813	O
drug	814	818	O
-	818	819	O
treated	819	826	O
animals	827	834	O
.	834	835	O

In	836	838	O
vivo	839	843	O
nuclear	844	851	O
magnetic	852	860	O
resonance	861	870	O
analysis	871	879	O
of	880	882	O
tumor	883	888	B-Pathological_formation
blood	889	894	B-Organism_substance
flow	895	899	O
in	900	902	O
linomide	903	911	B-Drug_or_compound
-	911	912	O
treated	912	919	O
animals	920	927	O
showed	928	934	O
localization	935	947	O
of	948	950	O
blood	951	956	B-Multi-tissue_structure
vessels	957	964	I-Multi-tissue_structure
almost	965	971	O
exclusively	972	983	O
to	984	986	O
the	987	990	O
periphery	991	1000	O
of	1001	1003	O
the	1004	1007	O
poorly	1008	1014	O
vascularized	1015	1027	O
tumors	1028	1034	B-Pathological_formation
with	1035	1039	O
a	1040	1041	O
significant	1042	1053	O
reduction	1054	1063	O
of	1064	1066	O
both	1067	1071	O
vascular	1072	1080	O
functionality	1081	1094	O
and	1095	1098	O
vasodilation	1099	1111	O
.	1111	1112	O

Histological	1113	1125	O
examination	1126	1137	O
of	1138	1140	O
tumors	1141	1147	B-Pathological_formation
from	1148	1152	O
linomide	1153	1161	B-Drug_or_compound
-	1161	1162	O
treated	1162	1169	O
animals	1170	1177	O
revealed	1178	1186	O
marked	1187	1193	O
avascularity	1194	1206	O
.	1206	1207	O

Treated	1208	1215	O
animals	1216	1223	O
also	1224	1228	O
displayed	1229	1238	O
a	1239	1240	O
2	1241	1242	O
.	1242	1243	O
4	1243	1244	O
-	1244	1245	O
fold	1245	1249	O
reduction	1250	1259	O
of	1260	1262	O
tumor	1263	1268	B-Pathological_formation
vascular	1269	1277	B-Gene_or_gene_product
endothelial	1278	1289	I-Gene_or_gene_product
growth	1290	1296	I-Gene_or_gene_product
factor	1297	1303	I-Gene_or_gene_product
mRNA	1304	1308	O
levels	1309	1315	O
.	1315	1316	O

Taken	1317	1322	O
together	1323	1331	O
,	1331	1332	O
our	1333	1336	O
data	1337	1341	O
indicate	1342	1350	O
that	1351	1355	O
in	1356	1358	O
VHL	1359	1362	O
disease	1363	1370	O
,	1370	1371	O
therapy	1372	1379	O
directed	1380	1388	O
at	1389	1391	O
inhibition	1392	1402	O
of	1403	1405	O
constitutively	1406	1420	O
expressed	1421	1430	O
VEGF	1431	1435	B-Gene_or_gene_product
induction	1436	1445	O
of	1446	1448	O
angiogenesis	1449	1461	O
by	1462	1464	O
VHL	1465	1468	B-Pathological_formation
tumors	1469	1475	I-Pathological_formation
may	1476	1479	O
constitute	1480	1490	O
an	1491	1493	O
effective	1494	1503	O
medical	1504	1511	O
treatment	1512	1521	O
.	1521	1522	O

